Secondary Outcome(s)
|
Changes from baseline in the 24-hour worst itch score from the Itch Numerical Rating Scale (Itch NRS)
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit control of disease activity (CDA)
[Time Frame: up to week 36]
|
Time to achieve complete remission (CR) while on minimal oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit complete remission (CR)/partial remission (PR) while off oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|
Incidence of treatment emergent adverse events (TEAEs)
[Time Frame: up to 46 weeks]
|
Number of participants (or their caregivers) who complete the (self-)administration training at study sites
[Time Frame: up to week 32]
|
Percentage of participants (or their caregivers) who successfully (self-)administer efgartigimod PH20 SC under site staff supervision
[Time Frame: up to week 35]
|
Proportion of participants who achieve an Investigator Global Assessment of Bullous Pemphigoid (IGA-BP) score of 0 while receiving efgartigimod PH20 SC or placebo and have been off oral corticosteroid (OCS) therapy for =8 weeks at week 36
[Time Frame: at week 36]
|
Proportion of participants who achieve control of disease activity (CDA) while receiving efgartigimod PH20 SC or placebo and remain free of relapse through week 36
[Time Frame: up to week 36]
|
Severity of serious adverse events (SAEs)
[Time Frame: up to 46 weeks]
|
Time to achieve complete remission (CR) while off oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit complete remission (CR)
[Time Frame: up to week 36]
|
Time to achieve relapse
[Time Frame: up to week 36]
|
Autoimmune Bullous Disease Quality of Life (ABQoL) scores over time
[Time Frame: up to week 36]
|
Changes from baseline in the 24-hour average itch score from the Itch Numerical Rating Scale (Itch NRS)
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit complete remission (CR) while off oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|
Percent change of Anti-BP180 and anti-BP230 antibodies from baseline over time
[Time Frame: up to 46 weeks]
|
Percent change of total IgG serum levels from baseline over time
[Time Frame: up to 46 weeks]
|
Proportion of participants who achieve an Investigator Global Assessment of Bullous Pemphigoid (IGA-BP) score of 0 or 1 while receiving efgartigimod PH20 SC or placebo at any time through week 36
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit relapse
[Time Frame: up to week 36]
|
Changes from baseline in the Bullous Pemphigoid Disease Area Index (BPDAI) activity score
[Time Frame: up to week 36]
|
Incidence of adverse events of special interest (AESIs)
[Time Frame: up to 46 weeks]
|
EuroQol 5-Dimension 5-Level (EQ-5D-5L) scores over time
[Time Frame: up to week 36]
|
The Aggregate Improvement Score (AIS) from the Glucocorticoid Toxicity Index (GTI)
[Time Frame: up to week 36]
|
The Glucocorticoid Toxicity Index Specific List (GTI-SL)
[Time Frame: up to week 36]
|
Time to achieve complete remission (CR)
[Time Frame: up to week 36]
|
Efgartigimod serum concentrations
[Time Frame: up to week 43]
|
Incidence of serious adverse events (SAEs)
[Time Frame: up to 46 weeks]
|
Number of participants (or their caregivers) who successfully (self-)administer efgartigimod PH20 SC under site staff supervision
[Time Frame: up to week 35]
|
Proportion of participants who achieve an Investigator Global Assessment of Bullous Pemphigoid (IGA-BP) score of 0 or 1 while receiving efgartigimod PH20 SC or placebo and have been off oral corticosteroid (OCS) therapy for =8 weeks at week 36
[Time Frame: at week 36]
|
Incidence of Antidrug antibodies (ADA) against efgartigimod (in serum) and antibodies produced against rHuPH20 (in plasma)
[Time Frame: up to 46 weeks]
|
Severity of treatment emergent adverse events (TEAEs)
[Time Frame: up to 46 weeks]
|
The Cumulative Worsening Score (CWS) from the Glucocorticoid Toxicity Index (GTI)
[Time Frame: up to week 36]
|
Time to achieve control of disease activity (CDA)
[Time Frame: up to week 36]
|
Cumulative dose of oral corticosteroid (OCS) from baseline to week 36
[Time Frame: up to week 36]
|
Cumulative oral corticosteroid (OCS) dose for the participant at the time points when they exhibit complete remission (CR) while on minimal oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|
Number of participants (or their caregivers) who are determined by site staff to be sufficiently competent in (self-)administering efgartigimod PH20 SC
[Time Frame: up to week 32]
|
Proportion of participants who receive rescue therapy before week 36
[Time Frame: at week 36]
|
Dermatology Life Quality Index (DLQI) scores over time
[Time Frame: up to week 36]
|
Percentage of participants (or their caregivers) who are determined by site staff to be sufficiently competent in (self-)administering efgartigimod PH20 SC
[Time Frame: up to week 32]
|
Percentage of participants (or their caregivers) who complete the (self-)administration training at study sites
[Time Frame: up to week 32]
|
Proportion of participants who are in complete remission (CR) while receiving efgartigimod PH20 SC or placebo and have been receiving minimal oral corticosteroid (OCS) therapy for =8 weeks at week 36
[Time Frame: at week 36]
|
Severity of adverse events of special interest (AESIs)
[Time Frame: up to 46 weeks]
|
Time to achieve complete remission (CR)/partial remission (PR) while off oral corticosteroid (OCS) therapy for =8 weeks
[Time Frame: up to week 36]
|